Design, synthesis, docking, and biochemical characterization of non-nucleoside SARS-CoV-2 RdRp inhibitors
Authors:
Open Access
- 21 January 2023
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 80, 117179
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Remdesivir for the Treatment of Covid-19 — Final ReportNew England Journal of Medicine, 2020
- Structure of the RNA-dependent RNA polymerase from COVID-19 virusScience, 2020
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trialThe Lancet, 2020
- Flavonoids as Antiviral Agents for Enterovirus A71 (EV-A71)Viruses, 2020
- A new coronavirus associated with human respiratory disease in ChinaNature, 2020
- Polypharmacology in HIV inhibition: can a drug with simultaneous action against two relevant targets be an alternative to combination therapy?European Journal of Medicinal Chemistry, 2018
- Nucleoside, Nucleotide, and Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B RNA-Dependent RNA-PolymeraseJournal of Medicinal Chemistry, 2011
- Glide: A New Approach for Rapid, Accurate Docking and Scoring. 2. Enrichment Factors in Database ScreeningJournal of Medicinal Chemistry, 2004
- Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking AccuracyJournal of Medicinal Chemistry, 2004
- Antiviral effect of flavonoids on human virusesJournal of Medical Virology, 1985